- Home
- GENC vs ENGN Comparison
GENC vs ENGN Comparison
Compare GENC & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- ENGN
- Stock Information
- Founded
- GENC 1894
- ENGN 1999
- Country
- GENC United States
- ENGN Canada
- Employees
- GENC N/A
- ENGN N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- ENGN
- Sector
- GENC Industrials
- ENGN
- Exchange
- GENC Nasdaq
- ENGN Nasdaq
- Market Cap
- GENC 215.0M
- ENGN 191.1M
- IPO Year
- GENC N/A
- ENGN N/A
- Fundamental
- Price
- GENC $15.06
- ENGN $3.37
- Analyst Decision
- GENC
- ENGN Buy
- Analyst Count
- GENC 0
- ENGN 7
- Target Price
- GENC N/A
- ENGN $23.29
- AVG Volume (30 Days)
- GENC 27.6K
- ENGN 83.9K
- Earning Date
- GENC 08-08-2025
- ENGN 09-09-2025
- Dividend Yield
- GENC N/A
- ENGN N/A
- EPS Growth
- GENC N/A
- ENGN N/A
- EPS
- GENC 0.99
- ENGN N/A
- Revenue
- GENC $113,166,000.00
- ENGN N/A
- Revenue This Year
- GENC N/A
- ENGN N/A
- Revenue Next Year
- GENC N/A
- ENGN N/A
- P/E Ratio
- GENC $15.29
- ENGN N/A
- Revenue Growth
- GENC 7.70
- ENGN N/A
- 52 Week Low
- GENC $10.80
- ENGN $2.65
- 52 Week High
- GENC $24.88
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- GENC 58.37
- ENGN 40.69
- Support Level
- GENC $14.72
- ENGN $2.95
- Resistance Level
- GENC $15.17
- ENGN $3.98
- Average True Range (ATR)
- GENC 0.68
- ENGN 0.27
- MACD
- GENC 0.03
- ENGN 0.02
- Stochastic Oscillator
- GENC 86.62
- ENGN 34.29
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.